ACCoRd Trial to Test Ninlaro Treatment for ASCT-Relapsed Multiple Myeloma
A new Phase 3 clinical trial called ACCoRd is underway to investigate the benefits of adding Ninlaro (ixazomib) – a proteasome inhibitor – to…
News
AbbVie, IMF Team Up to Study Gene Mutation in Myeloma Outcomes
AbbVie and the International Myeloma Foundation are collaborating to study the role of a genetic mutation — the t(11;14) translocation — in multiple myeloma treatments…
SELLAS Vaccine More Than Doubles Time to Myeloma Progression, Phase 2 Trial Shows
SELLAS Life Sciences’  Galinpepimut-S vaccine more than doubles the time it takes for high-risk multiple myeloma patients’ cancer to worsen, a Phase 2 clinical trial shows.
Medicinal Cannabis Safe and Effective for Pain, Chemo Side Effects, Journal Says
The supervised use of medicinal cannabis is safe and effective at relieving pain and reducing chemotherapy-induced nausea and vomiting in cancer patients, an increasing body of…
Myeloma Patients Refractory to Revlimid May Benefit from Ninlaro, Pomalyst, Dexamethasone Combo
Multiple myeloma patients who failed prior Revlimid (lenalidomide) treatment may benefit from a triple oral combo treatment with Ninlaro (ixazomib), Pomalyst (pomalidomide) and dexamethasone, the results…
Trial to Explore Benefits of Exercise Before Autologous Stem Cell Transplant in Myeloma Patients
A new clinical trial will determine if an exercise program before an autologous stem cell transplant can improve treatment-related side effects in multiple myeloma patients. The…
Seattle Genetics Starts Phase 1 Trial Testing SGN-CD48A in Relapsed or Refractory Myeloma
Seattle Genetics‘ investigational therapy SGN-CD48A, being evaluated in a Phase 1 clinical trial for relapsed or refractory multiple myeloma, was successfully delivered…
Patients with MGUS Have a Low But Persistent Risk of Multiple Myeloma, Study Finds
Patients with a condition called monoclonal gammopathy of undetermined significance, characterized by the presence of the abnormal monoclonal or M protein, have a small but…
Phase 1/2 Trial of Medigene’s MDG1011 Immunotherapy in Blood Cancer Patients Set to Begin
A Phase 1/2 clinical trial testing an experimental T-cell therapy for the first time in human patients will begin in the coming weeks after receiving…
New Test Speeds Time to Determine Success of Bone Marrow Transplants
Scientists have developed a new test that shortens the time it takes to assess the success of bone marrow transplants — to a few days…
